



WHO Guidelines Meeting on Preventive Therapy and Case Finding for TB in People Living with HIV.

**25-27 January 2010
Kofi Anan Conference Room
World Health Organization, Geneva, Switzerland**

PICOT Questions / Meeting Objectives

Population of interest

Intervention to be assessed

Comparison with current standard of care

Outcome for patients and community

Timeline in which each outcome needs to be assessed

Question 1: Define the optimal duration and drug regimen (e.g., INH, RIF, etc.) for treatment of LTBI to reduce the risk of developing TB among PLHIV

Question 2: Define the optimal time to start considering IPT (i.e., should immune status be considered and should IPT be started with ART).

Question 3: Determine whether PLHIV who had received TB treatment in the past be provided secondary treatment of LTBI to prevent re-infection or recurrence of Tuberculosis.

Question 4: Determine whether treatment for LTBI among PLHIV lead to significant developments of mono-resistance against the drugs used for LTBI treatment?

Question 5: Determine whether low adherence rates to LTBI treatment be a barrier to the implementation of LTBI treatment among PLHIV.

Question 6: Determine whether the provision of treatment for LTBI is cost-effective.

Question 7: PPD in resource-limited settings

Question 8: Determine the best combination of signs, symptoms and diagnostic procedures (e.g., smear microscopy, radiography, serum-based tests such as IGRA, etc.) as screening tools to determine eligibility for LTBI treatment and to diagnose TB among PLHIV? (Feasibility considerations included)